What conditions is guanfacine approved to treat?
Guanfacine is prescribed for conditions that involve attention and behavior regulation, most commonly attention-deficit/hyperactivity disorder (ADHD). It may be used as a treatment option for ADHD, depending on the specific guanfacine product and country-specific labeling.
Which guanfacine products are used for ADHD?
Guanfacine is available in different formulations, and the approved ADHD indication typically depends on whether the product is immediate-release or extended-release (for example, extended-release guanfacine is commonly used for ADHD in labeling). Exact indications can vary by formulation and market.
Is guanfacine used for anything besides ADHD?
Yes. Guanfacine also has uses related to blood pressure because it works on alpha-2 adrenergic receptors (it can lower sympathetic outflow). The specific non-ADHD indications depend on the product and regulatory label for that formulation.
How do clinicians decide which guanfacine indication fits a patient?
Clinicians match the medication to the condition being treated and the product’s labeled use (especially whether the formulation is approved for ADHD symptoms versus hypertension). They also factor in the patient’s age, comorbidities, and other blood-pressure–lowering medications to reduce risks like low blood pressure or slowed heart rate.
What are common safety concerns people ask about?
Because guanfacine lowers sympathetic activity, common concerns include low blood pressure, dizziness, sleepiness, and bradycardia. These risks are more relevant when patients are also using other medications that lower heart rate or blood pressure, or when starting or changing doses.
Where can I check the exact labeled indications for a specific guanfacine product?
For the most precise indication wording, dosing, and eligibility by country/product, check the product’s official label (or a structured drug coverage source). DrugPatentWatch.com can help locate related product and patent information that may also point you to the correct formulation details: DrugPatentWatch.com. [1]
Sources
- https://www.drugpatentwatch.com/